Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Price Target at $267.87

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $267.87.

IQV has been the topic of a number of analyst reports. Truist Financial cut their price objective on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a report on Monday, October 14th. Morgan Stanley lifted their price objective on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Robert W. Baird lifted their price objective on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. Finally, Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective on the stock.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board raised its stake in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares during the period. Lazard Asset Management LLC increased its position in shares of IQVIA by 0.9% during the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after buying an additional 30,014 shares during the period. Farallon Capital Management LLC increased its position in shares of IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after buying an additional 86,870 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of IQVIA by 3.8% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after buying an additional 92,293 shares during the period. Finally, Capital Research Global Investors increased its position in shares of IQVIA by 7.2% during the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after buying an additional 143,533 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

NYSE IQV opened at $236.69 on Friday. The company has a fifty day simple moving average of $239.08 and a 200 day simple moving average of $231.08. IQVIA has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market cap of $43.15 billion, a P/E ratio of 30.74, a PEG ratio of 2.22 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.22 EPS. Sell-side analysts predict that IQVIA will post 10.25 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.